-

Ossium Health to Exhibit at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health, a clinical-stage bioengineering company with a first-of-its-kind bone marrow banking platform for processing and deploying hematopoietic stem cells and stem cell-based therapies, announced that the company will be exhibiting at the Transplantation & Cellular Therapy (Tandem) Meetings of ASTCT and CIBMTR, to be held on February 12-15, 2025 in Honolulu, HI.

Attendees are encouraged to visit Ossium Health at Booth 629 to learn more about the company’s latest developments, including:

  • PRESERVE I Clinical Trial: This ongoing trial is actively recruiting patients and aims to evaluate allogeneic HCT with Ossium’s organ donor bone marrow for patients with hematologic malignancies.
  • HOPE Program: Ossium’s expanded access program is available for patients in need of an allogeneic HCT that are unable to enroll in PRESERVE I.

Additionally, the company will present Poster 221, A Potency Assay Matrix for Establishing Consistency of Manufactured Mesenchymal Stem/Stromal Cells, on Thursday, February 13 at 6:45pm HST in Exhibit Hall 3 (HCC) during the Cellular and Gene Therapy: Regulatory and Processing poster session.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, Chief Executive Officer, President and Co-Founder, and Erik Woods, Chief Science Officer, Executive Vice President and Co-Founder. Ossium Health’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit https://ossiumhealth.com.

Follow the company on LinkedIn at https://www.linkedin.com/company/ossiumhealth/ and X at https://x.com/ossiumhealth.

Contacts

Jane Griffin
Ossium Health, Inc.
415-513-5535
press@ossiumhealth.com

David Schull
Russo Partners
858-717-2310
david.schull@russopartnersllc.com

Ossium Health


Release Versions

Contacts

Jane Griffin
Ossium Health, Inc.
415-513-5535
press@ossiumhealth.com

David Schull
Russo Partners
858-717-2310
david.schull@russopartnersllc.com

Social Media Profiles
More News From Ossium Health

Susannah Cantrell Joins Ossium Health as Chief Commercial Officer

SAN FRANCISCO--(BUSINESS WIRE)--Susannah Cantrell, PhD, has joined Ossium Health's leadership team as Chief Commercial Officer (CCO)....

Ossium Health to Participate at the 66th American Society of Hematology Annual Meeting and Exposition

SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health will exhibit at the American Society of Hematology (ASH) Annual Meeting and Exposition on December 7-10, 2024 in San Diego, CA....

Ossium Health Secures BARDA Contract to Advance Bone Marrow Bank for Radiological and Nuclear Emergencies

SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health secures BARDA contract to advance bone marrow bank for radiological and nuclear emergencies...
Back to Newsroom